215 related articles for article (PubMed ID: 35620896)
21. Baseline stimulated thyroglobulin level as a good predictor of successful ablation after adjuvant radioiodine treatment for differentiated thyroid cancers.
Fatima N; uz Zaman M; Ikram M; Akhtar J; Islam N; Masood Q; Zaman U; Zaman A
Asian Pac J Cancer Prev; 2014; 15(15):6443-7. PubMed ID: 25124640
[TBL] [Abstract][Full Text] [Related]
22. Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer--is there a need for radioactive iodine therapy?
Ibrahimpasic T; Nixon IJ; Palmer FL; Whitcher MM; Tuttle RM; Shaha A; Patel SG; Shah JP; Ganly I
Surgery; 2012 Dec; 152(6):1096-105. PubMed ID: 23158181
[TBL] [Abstract][Full Text] [Related]
23. Non-suppressed thyrotropin and elevated thyroglobulin are independent predictors of recurrence in differentiated thyroid carcinoma.
Böhm J; Kosma VM; Eskelinen M; Hollmen S; Niskanen M; Tulla H; Alhava E; Niskanen L
Eur J Endocrinol; 1999 Nov; 141(5):460-7. PubMed ID: 10576761
[TBL] [Abstract][Full Text] [Related]
24. Effects of low-dose and high-dose postoperative radioiodine therapy on the clinical outcome in patients with small differentiated thyroid cancer having microscopic extrathyroidal extension.
Han JM; Kim WG; Kim TY; Jeon MJ; Ryu JS; Song DE; Hong SJ; Shong YK; Kim WB
Thyroid; 2014 May; 24(5):820-5. PubMed ID: 24328997
[TBL] [Abstract][Full Text] [Related]
25. Long-term consequence of elevated thyroglobulin in differentiated thyroid cancer.
Yim JH; Kim EY; Bae Kim W; Kim WG; Kim TY; Ryu JS; Gong G; Hong SJ; Yoon JH; Shong YK
Thyroid; 2013 Jan; 23(1):58-63. PubMed ID: 22973946
[TBL] [Abstract][Full Text] [Related]
26. Risk Stratification of Pediatric Patients with Differentiated Thyroid Cancer: Is Total Thyroidectomy Necessary for Patients at Any Risk?
Sugino K; Nagahama M; Kitagawa W; Ohkuwa K; Uruno T; Matsuzu K; Suzuki A; Tomoda C; Hames KY; Akaishi J; Masaki C; Ito K
Thyroid; 2020 Apr; 30(4):548-556. PubMed ID: 31910105
[No Abstract] [Full Text] [Related]
27. Long-term clinical outcome of differentiated thyroid cancer patients with undetectable stimulated thyroglobulin level one year after initial treatment.
Han JM; Kim WB; Yim JH; Kim WG; Kim TY; Ryu JS; Gong G; Sung TY; Yoon JH; Hong SJ; Kim EY; Shong YK
Thyroid; 2012 Aug; 22(8):784-90. PubMed ID: 22780573
[TBL] [Abstract][Full Text] [Related]
28. Intermediate-risk thyroid carcinoma: indicators of a poor prognosis.
Faro FN; Bezerra ÂMLB; Scalissi NM; Cury AN; Marone MM; Ferraz C; do Prado Padovani R
Arch Endocrinol Metab; 2021 May; 64(6):764-771. PubMed ID: 34033287
[TBL] [Abstract][Full Text] [Related]
29. Outcomes of patients with differentiated thyroid cancer risk-stratified according to the American thyroid association and Latin American thyroid society risk of recurrence classification systems.
Pitoia F; Bueno F; Urciuoli C; Abelleira E; Cross G; Tuttle RM
Thyroid; 2013 Nov; 23(11):1401-7. PubMed ID: 23517313
[TBL] [Abstract][Full Text] [Related]
30. Extranodal extension of metastatic papillary thyroid carcinoma: correlation with biochemical endpoints, nodal persistence, and systemic disease progression.
Lango M; Flieder D; Arrangoiz R; Veloski C; Yu JQ; Li T; Burtness B; Mehra R; Galloway T; Ridge JA
Thyroid; 2013 Sep; 23(9):1099-105. PubMed ID: 23421588
[TBL] [Abstract][Full Text] [Related]
31. Patient Age Is an Independent Risk Factor of Relapse of Differentiated Thyroid Carcinoma and Improves the Performance of the American Thyroid Association Stratification System.
Trimboli P; Piccardo A; Signore A; Valabrega S; Barnabei A; Santolamazza G; Di Paolo A; Stati V; Chiefari A; Vottari S; Simmaco M; Ferrarazzo G; Ceriani L; Appetecchia M; Giovanella L
Thyroid; 2020 May; 30(5):713-719. PubMed ID: 31973653
[No Abstract] [Full Text] [Related]
32. Metastatic differentiated thyroid cancer with negative serum stimulated Tg but positive post-therapeutic
Li X; Li H; Yan Y; Xu H; Wang Y; Liu Y; Gao R
Endocrine; 2023 Oct; 82(1):117-125. PubMed ID: 37209260
[TBL] [Abstract][Full Text] [Related]
33. Outcomes after radioiodine ablation in patients with thyroid cancer: Long-term follow-up of a Chinese randomized clinicaltrial.
Dong P; Qu Y; Yang L; Xiao L; Huang R; Li L
Clin Endocrinol (Oxf); 2021 Nov; 95(5):782-789. PubMed ID: 34368999
[TBL] [Abstract][Full Text] [Related]
34. Surgical approach and radioactive iodine therapy for small well-differentiated thyroid cancer.
Momesso DP; Vaisman F; Caminha LS; Pessoa CH; Corbo R; Vaisman M
J Endocrinol Invest; 2014 Jan; 37(1):57-64. PubMed ID: 24464451
[TBL] [Abstract][Full Text] [Related]
35. Risk factors for recurrence of differentiated thyroid carcinoma in children and adolescents: A retrospective cohort study.
Jia S; Tang D; Peng W
Medicine (Baltimore); 2023 Dec; 102(50):e36585. PubMed ID: 38115329
[TBL] [Abstract][Full Text] [Related]
36. Histology is more ιmportant than persistent anti-Tg antibodies for progression of differentiated thyroid cancer.
Karapanou O; Saltiki K; Simeakis G; Botoula E; Tsagarakis S; Alevizaki M; Vlassopoulou B
Clin Endocrinol (Oxf); 2021 Jul; 95(1):217-223. PubMed ID: 33682167
[TBL] [Abstract][Full Text] [Related]
37. Pre-ablation stimulated thyroglobulin is a better predictor of recurrence in pathological N1a papillary thyroid carcinoma than the lymph node ratio.
Chang YW; Kim HS; Jung SP; Kim HY; Lee JB; Bae JW; Son GS
Int J Clin Oncol; 2016 Oct; 21(5):862-868. PubMed ID: 26837274
[TBL] [Abstract][Full Text] [Related]
38. Low but measurable stimulated serum thyroglobulin levels <2 µg/L frequently predict incomplete response in differentiated thyroid cancer patients.
Aldawish M; Jha N; McEwan AJ; Severin D; Ghosh S; Morrish DW
Endocr Res; 2014; 39(4):157-63. PubMed ID: 24460082
[TBL] [Abstract][Full Text] [Related]
39. Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines.
Mitchell AL; Gandhi A; Scott-Coombes D; Perros P
J Laryngol Otol; 2016 May; 130(S2):S150-S160. PubMed ID: 27841128
[TBL] [Abstract][Full Text] [Related]
40. Is there a role for diagnostic scans in the management of intermediate-risk thyroid cancer?
Danilovic DLS; Coura-Filho GB; Recchia GM; Castroneves LA; Marui S; Buchpiguel CA; Hoff AO; Kopp P
Endocr Relat Cancer; 2022 Aug; 29(8):475-483. PubMed ID: 35613335
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]